

**Critical Care Guidelines
FOR CRITICAL CARE USE ONLY**



**KETAMINE
For bronchodilation in asthma**

PRESENTATION: Vial containing 500mg in 10ml (50mg/ml) of ketamine

INDICATION: Refractory status asthmaticus in ventilated patients not responding to conventional treatments (unlicensed indication)

DOSE AND ADMINISTRATION:
The evidence on the use of ketamine is mostly based on isolated case reports.

ICU STANDARD CONTINUOUS INFUSION

2500mg in 50mL (undiluted)

Start at 500micrograms/kg/hr and adjust rate according to the response. Maintenance infusion range is 0.15-2.5mg/kg/hr.

For a 70 kg patient 500micrograms/kg/hr is 0.7ml/hr (35mg/hr)

Administer intravenously via central access device.

Ketamine has a low pH and may cause venous irritation and tissue damage in cases of extravasation.

Ketamine does **not** need to be administered in a locked syringe in intensive care.

CONCENTRATION: 50mg/ml

STABILITY: Physically and chemically stable for 24 hours at room temperature

References

1. Summary of Product Characteristics, Ketamine 50mg/ml injection, Hameln pharmaceuticals, www.medicines.org.uk/emc/product/6935/smpc last updated 20/03/2018
2. Injectable Medicines Guide online accessed on 21/09/2018
3. Stanley D, Tunnincliffe W, Management of life-threatening asthma in adults; Continuing Education in Anaesthesia Critical Care & Pain, Vol 8(3);2008;p95–99
4. Goyal S, Agrawal A, Ketamine in status asthmaticus: A review; Indian Journal of Critical Care Medicine, vol17(3); 2013;p 154-161

Title: KETAMINE	
ID:	Authors: Agata Paczek
Category:	Document Version: 1.0
Status Draft/Final: Final	Review Date: June 2021
Authoriser: QIT Editorial Board	Authorisation Date: June 2019
Date added to Intranet	
Key Words	
Comments	